Tempest Therapeutics

Yahoo Finance • 10 months ago

11 Hot Healthcare Stocks To Buy Now

In this article, we will be taking a look at 11 hot healthcare stocks to buy now. To skip our detailed analysis of the healthcare sector, you can go directly to see the 5 Hot Healthcare Stocks To Buy Now. Healthcare is a vital part of dai... Full story

Yahoo Finance • 12 months ago

Tempest to Present at the 35th Annual Piper Sandler Healthcare Conference

BRISBANE, Calif., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-classi therapeutics that combine both targeted and immune-mediated mechanisms, today ann... Full story

Yahoo Finance • 12 months ago

Tempest Reports Third Quarter 2023 Financial Results and Provides Business Update

TPST-1120 demonstrates superiority compared to standard of care across multiple study endpoints in randomized first-line HCC studyNew capital strengthens balance sheet and extends cash runway into 2025 BRISBANE, Calif., Nov. 08, 2023 (G... Full story

Yahoo Finance • last year

Market Today: Pfizer's Acquisition of Seagen Under Review, NextEra Energy Rebounds, and Tempest ...

The S&P 500, Dow Jones Industrial Average, and Nasdaq Composite all saw gains on 10-11-2023, with the S&P 500 advancing by 0.43%, the Dow Jones finishing 0.19% higher, and the Nasdaq Composite rising by 0.71%. The 10-year Treasury yield fe... Full story

Yahoo Finance • last year

Tempest Adopts Limited Duration Stockholder Rights Plan

BRISBANE, Calif., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-classi therapeutics that combine both targeted and immune-mediated mechanisms, today ann... Full story

Yahoo Finance • last year

Tempest Releases New Data Demonstrating Superiority of TPST-1120 Arm Across Multiple Study Endpoints in Randomized First-Line HCC Study

New data package reveals improvements in multiple categories for TPST-1120 combined with atezolizumab + bevacizumab versus standard of care atezolizumab + bevacizumab in a global Phase 1b/2 study30% confirmed ORR achieved in TPST-1120 arm... Full story

Yahoo Finance • last year

Tempest to Report New and Updated Data from Global Randomized Combination Study of TPST-1120 in First-Line Hepatocellular Carcinoma

BRISBANE, Calif., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted and immune-mediated mechanisms, today ann... Full story

Yahoo Finance • last year

Tempest Announces Expanded Role for Sam Whiting, M.D., Ph.D., as Chief Medical Officer and Head of Research and Development

BRISBANE, Calif., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-classi therapeutics that combine both targeted and immune-mediated mechanisms, announce... Full story

Yahoo Finance • last year

Tempest to Present at the H.C. Wainwright 25th Annual Global Investment Conference

BRISBANE, Calif., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-classi therapeutics that combine both targeted and immune-mediated mechanisms, announce... Full story

Yahoo Finance • last year

Tempest Reports First Quarter 2023 Financial Results and Provides Business Update

BRISBANE, Calif., May 10, 2023 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-classi therapeutics that combine both targeted and immune-mediated mechanisms, today repo... Full story

Yahoo Finance • 2 years ago

Tempest Announces Positive Early Results from Global Randomized Phase 1b/2 Combination Study of TPST-1120 in First-Line Hepatocellular Carcinoma

Positive randomized data with TPST-1120 combined with atezolizumab + bevacizumab compared head-to-head with atezolizumab + bevacizumab The addition of TPST-1120 resulted in a clinically-meaningful improvement in both confirmed and unconfir... Full story

Yahoo Finance • 2 years ago

Tempest to Report Early Results from Global Randomized Phase 1b/2 Combination Study of TPST-1120 in First-Line Hepatocellular Carcinoma

BRISBANE, Calif., April 27, 2023 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted and immune-mediated mechanisms, today an... Full story

Yahoo Finance • 2 years ago

Tempest Announces New Translational and Preclinical Data Presented at the 2023 AACR Annual Meeting

BRISBANE, Calif., April 17, 2023 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted and immune-mediated mechanisms, today an... Full story

Yahoo Finance • 2 years ago

Tempest to Present New Translational and Preclinical Data at the 2023 AACR Annual Meeting

BRISBANE, Calif., March 14, 2023 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted and immune-mediated mechanisms, today an... Full story

Yahoo Finance • 2 years ago

Tempest to Present at the Piper Sandler 34th Annual Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company focused on developing first-in-class therapeutics that combine both targeted and immune-mediated... Full story

Yahoo Finance • 2 years ago

Tempest Presents Data Showing TPST-1120-Induced Pharmacodynamic Changes Consistent with Clinical Benefit Observed in Patients with Cancer

TPST-1120 Late-breaking Poster Presentation at SITC Annual Meeting Second Poster Presentation Demonstrates that Dual Blockade of EP2 and EP4 PGE2 Receptors with TPST-1495 is an Optimal Approach for Drugging the Prostaglandin Pathway SOUTH... Full story

Yahoo Finance • 2 years ago

Tempest Reports Third Quarter 2022 Financial Results and Provides Business Update

SOUTH SAN FRANCISCO, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted and immune-mediated mechanisms... Full story

Yahoo Finance • 2 years ago

Tempest Announces Data Presentations, including a Late-Breaking Presentation on TPST-1120, at the SITC Annual Meeting

SOUTH SAN FRANCISCO, Calif., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted and immune-mediated mechanisms... Full story

Yahoo Finance • 2 years ago

Tempest to Present at the H.C. Wainwright 24th Annual Global Investment Conference

SOUTH SAN FRANCISCO, Calif., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted and immune-mediated mechanism... Full story

Yahoo Finance • 2 years ago

Tempest Reports Second Quarter 2022 Financial Results and Provides Business Update

SOUTH SAN FRANCISCO, Calif., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted and immune-mediated mechanisms... Full story